Media Summary: Dr Sara Tolaney highlights exploratory biomarker analyses from the phase 3 ASCENT-03 trial evaluating Sacituzumab govitecan improves PFS in first-line metastatic TNBC patients unable to receive PD-(L)1 inhibitors Dr Javier ... Dr Sara Tolaney speaks to ecancer about an exploratory biomarker analyses from the phase 3 ASCENT-04/KEYNOTE-D19 study ...
Sacituzumab Govitecan Improves Pfs Across - Detailed Analysis & Overview
Dr Sara Tolaney highlights exploratory biomarker analyses from the phase 3 ASCENT-03 trial evaluating Sacituzumab govitecan improves PFS in first-line metastatic TNBC patients unable to receive PD-(L)1 inhibitors Dr Javier ... Dr Sara Tolaney speaks to ecancer about an exploratory biomarker analyses from the phase 3 ASCENT-04/KEYNOTE-D19 study ... Hope Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, provides an overview of ... Dr Hope Rugo speaks to ecancer about the use of Scott Tagawa, MD, MS, FACP, Weill Cornell Medical Center, New York, NY, takes us
Data from the ASCENT-04/KEYNOTE-D19 trial showed that frontline Sara Tolaney, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, provides an overview of a biomarker analysis of the Phase III ... At this year's European Society for Medical Oncology (ESMO) Congress in Madrid, Spain, Dr. Kevin Kalinsky, Director of the Glenn ... Kevin Kalinsky, MD, MS, Emory University Hospital, Atlanta, GA, discusses the results of a study looking at real-world Aditya Bardia, MD, MPH, assistant professor of medicine, Harvard Medical School, attending physician, Medical Oncology, ... Filipa Lynce, MD, provides an overview of a study at Dana-Farber Cancer Institute evaluating the safety and effectiveness of ...
